On September 8, BEONE MEDICINES fell 3.07% in regular trading, trading at HK$208.4/share, with turnover of HK$161 million, extending its multi-day pullback as the market continues to digest the implications of the company's recently announced US Medicaid drug pricing agreement.

On September 1, BEONE MEDICINES announced a voluntary agreement with the US government to supply tislelizumab (Tevimbra) through the Medicaid program at negotiated prices for eligible patients, expected to cover approximately 8% of the drug's approved indication patient population in the US. While multiple brokerages have noted that the pricing framework for core hematology products such as zanubrutinib (Brukinsa) and sonrotoclax remains unaffected, and have maintained buy ratings citing limited near-term financial impact and potential for volume expansion, broader market concerns over US drug pricing policy continue to weigh on sentiment.

Within the Biotechnology sector, overall performance was subdued. Among peers, AKESO fell 0.26%, INNOVENT BIO fell 1.38%, EVEREST MED fell 0.96%, METIS TECHBIO-P rose 9.28%, and DUALITYBIO was flat at 0.06%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)